Drug Profile
OBI 3424
Alternative Names: AST-3424; OBI-3424; TH-3424Latest Information Update: 03 May 2024
Price :
$50
*
At a glance
- Originator Threshold Pharmaceuticals
- Developer Ascentawits Pharmaceuticals; National Cancer Institute (USA); OBI Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
- Phase I/II Liver cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 21 Mar 2024 OBI Pharma terminates a phase I/II trial in Solid tumour and Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV), due to lack of sufficient evidence of clinical activity (NCT03592264)
- 20 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the European Society for Medical Oncology Congress (ESMO-2023)
- 03 Jun 2022 Safety and pharmacokinetic data from a phase I part of phase I/II trial in Solid tumours presented at 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)